The Limited Times

Now you can see non-English news...

New Coronary Pneumonia | The University of Hong Kong and the Mainland developed a nasal spray vaccine approved for clinical trials

2020-09-09T12:33:15.204Z


The State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Medicine, The University of Hong Kong, announced that the influenza virus carrier new coronavirus vaccine developed with Xiamen University and Beijing Wantai Biotechnology has been approved by the National Medical Products Administration for clinical trials. The University of Hong Kong stated that this is currently the only nasal spray new coronary pneumonia vaccine that has entered clinical trials.


Social News

Written by: Li Enci

2020-09-09 20:14

Last update date: 2020-09-09 20:14

The State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Medicine, The University of Hong Kong, announced that the influenza virus carrier new coronavirus vaccine developed with Xiamen University and Beijing Wantai Biotechnology has been approved by the National Medical Products Administration for clinical trials.

The University of Hong Kong stated that this is currently the only nasal spray new coronary pneumonia vaccine that has entered clinical trials.

The University of Hong Kong stated that the research team used a vaccine technology platform similar to the preparation of influenza virus vaccines to prepare vaccine seeds, including the use of chicken embryo production systems, cell factories, or cell fermentation tanks for mass cultivation.

The vaccine can operate as a nasal spray and can target both the new coronavirus and influenza virus.

This vaccine research project is supported by the Ministry of Science and Technology in China. The team of Professor Honglin Chen from the University of Hong Kong has cooperated with Xiamen University and Beijing Wantai to use the nasal spray influenza virus vector new coronary pneumonia vaccine produced by MDCK.

The vaccine has passed the emergency approval of the National Medical Products Administration and has been approved to carry out clinical trials. It is currently the only nasal spray new coronary pneumonia vaccine that has entered clinical trials.

The vaccine can activate the local mucosal immune response and systemic immune response by simulating the natural infection pathway of respiratory viruses, thereby exerting a highly targeted protective effect.

The vaccine can operate as a nasal spray, which can target both the new coronavirus and influenza virus.

(Photo/Photo by Gao Zhongming)

▼List of reopening and continued restrictions starting on September 11▼

+19

+19

+19

New Crown Vaccine | China's three vaccine packaging box information reveals vaccination location and delivery procedures

[New Coronary Pneumonia] A vaccine will be available at the end of the year?

8 Tips for Price Effectiveness

New Coronary Pneumonia | Liang Zhuowei: The vaccine mainly reduces the risk of death and serious complications, non-immune infection

[Russian Vaccines] Vaccinations may be given priority, teachers reacted coldly, unions call for boycott

New Coronary Pneumonia|35% of Hong Kong people can get 9 vaccine candidates under COVAX next year

New crown pneumonia new crown pneumonia vaccine

Source: hk1

All news articles on 2020-09-09

You may like

News/Politics 2024-03-07T08:05:51.578Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.